Healthcare · Biotechnology
Price
$1.93
Market Cap
$85.7M
Employees
5
Beta
-0.95
Avg Volume
778,695
CEO
Paul A. Romness
Business Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Business History
Price Overview
Last updated: Jul 1, 2026 10:32am (just now)$1.86
-0.04 (-2.11%)
Day Range
$1.85 – $1.93
52-Week Range
$1.15 – $2.57
50-Day MA
$1.76
200-Day MA
$1.67
Volume
122,339.00
Share Structure
Outstanding
44,538,106.00
Float
25,399,747.00
Free Float
57.0%
Normal free float
— 57.0% of shares trade freely, ~43% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-1.96
Stock Price: $1.93
EPS (Diluted): -0.98
EPS (Diluted): -0.98
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
-6.72
Stock Price: $1.93
Total Equity: -$6.10M
Shares: 29,253,000
Total Equity: -$6.10M
Shares: 29,253,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.48
Market Cap: $85.74M
Total Debt: $0.00
Cash: $269,830
EBITDA: -$28.39M
Total Debt: $0.00
Cash: $269,830
EBITDA: -$28.39M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$40.7M
Market Cap: $85.74M
Total Debt: $0.00
Cash: $269,830
Total Debt: $0.00
Cash: $269,830
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.93
Revenue: $0.00
Shares: 29,253,000
Revenue: $0.00
Shares: 29,253,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$363,085
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$28.71M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$28.75M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
2,584.4%
Net Income: -$28.75M
Total Equity: -$6.10M
Total Equity: -$6.10M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
407.6%
Operating Income: -$28.71M
Tax Rate: 0.0%
Equity: -$6.10M
Total Debt: $0.00
Cash: $269,830
Tax Rate: 0.0%
Equity: -$6.10M
Total Debt: $0.00
Cash: $269,830
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.03
Current Assets: $332,912
Current Liabilities: $11.76M
Current Liabilities: $11.76M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$6.10M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: -$6.10M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 29,253,000
Shares: 29,253,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$-0.21
Total Equity: -$6.10M
Shares: 29,253,000
Shares: 29,253,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-486.75
Operating CF: -$14.24B
CapEx: -$466,423
Shares: 29,253,000
CapEx: -$466,423
Shares: 29,253,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.93
Stock Price: $1.93
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$28.75M
Net Income: -$28.75M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares OSTX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 1, 2026 9:31am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $1.2M | $805 | $4,220 | $2,780 | $363,085 |
| Gross Profit | -$1.2M | $-805 | $-4,220 | $-2,780 | $-363,085 |
| Operating Expenses | $3.7M | $4.4M | $4.3M | $6.8M | $28.3M |
| Operating Income | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.7M |
| Net Income | -$7.4M | -$6.3M | -$7.8M | -$8.9M | -$28.8M |
| EBITDA | -$4.8M | -$4.4M | -$4.3M | -$6.8M | -$28.4M |
| EPS | $-0.33 | $-0.28 | $-0.39 | $-0.52 | $-0.98 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 1, 2026 9:31am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $80,788 | $171,480 | $38,982 | $5.5M | $269,830 |
| Total Current Assets | $312,815 | $496,835 | $790,032 | $5.5M | $332,912 |
| Total Assets | $325,891 | $509,105 | $798,082 | $5.5M | $6.8M |
| Current Liabilities | $3.5M | $6.1M | $24.7M | $4.6M | $11.8M |
| Long-Term Debt | $7.1M | $10.3M | $0 | $0 | $0 |
| Total Liabilities | $11.8M | $18.1M | $24.8M | $4.7M | $12.9M |
| Total Equity | -$11.5M | -$17.6M | -$24.0M | $811,487 | -$6.1M |
| Retained Earnings | -$15.2M | -$21.6M | -$29.5M | -$40.4M | -$67.2M |
Cash Flow (Annual)
Last updated: Jul 1, 2026 9:31am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.2B |
| Capital Expenditure | $-11,934 | $0 | $0 | $0 | $-466,423 |
| Free Cash Flow | -$4.4M | -$3.8M | -$3.0M | -$7.3M | -$14.2B |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$1.2M | $90,692 | $-132,498 | $5.5M | -$5.3B |
Analyst Estimates (Annual)
Last updated: Jul 1, 2026 9:31am (1h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$32.9M $32.2M – $33.6M
|
$59.2M $58.9M – $59.5M
|
$94.4M $93.9M – $94.9M
|
$121.4M $120.8M – $122.0M
|
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$4.4M -$4.4M – -$4.4M
|
$339,500 -$25.9M – $23.2M
|
$5.4M $5.3M – $5.4M
|
$10.8M $10.8M – $10.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 1, 2026 9:31am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +99.9% | -424.2% | +34.1% | -12,960.6% |
| Operating Income Growth | +8.1% | +2.3% | -56.9% | -321.3% |
| Net Income Growth | +15.7% | -24.6% | -14.0% | -223.7% |
| EBITDA Growth | +8.1% | +2.4% | -57.4% | -315.8% |
Insider Trading (Recent)
Last updated: Jul 1, 2026 9:31am (1h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2024-12-05 | Romness Paul A. | A-Award | 500,000.00 | $1.86 | $930,000 |
| 2026-01-22 | McKean-Dieser Avril Suzette | A-Award | 50,000.00 | $1.34 | $67,000 |
| 2026-01-22 | Search Theodore F. | A-Award | 50,000.00 | $1.34 | $67,000 |
| 2026-01-22 | Ciccio John | A-Award | 50,000.00 | $1.34 | $67,000 |
| 2026-01-22 | Acevedo Christopher P. | A-Award | 100,000.00 | $1.34 | $134,000 |
| 2026-01-22 | PETIT ROBERT | A-Award | 100,000.00 | $1.34 | $134,000 |
| 2026-01-22 | Romness Paul A. | A-Award | 1,000,000.00 | $1.34 | $1.3M |
| 2026-01-22 | Jarry Olivier Roger | A-Award | 50,000.00 | $1.34 | $67,000 |
| 2026-01-22 | Galzahr Karim | A-Award | 50,000.00 | $1.34 | $67,000 |
| 2025-10-21 | Romness Paul A. | A-Award | 1,000,000.00 | $1.80 | $1.8M |
| 2025-10-21 | Search Theodore F. | A-Award | 140,000.00 | $1.80 | $252,000 |
| 2025-10-21 | PETIT ROBERT | A-Award | 500,000.00 | $1.80 | $900,000 |
| 2025-10-21 | Romness Paul A. | A-Award | 1,950,000.00 | $1.80 | $3.5M |
| 2025-10-21 | Jarry Olivier Roger | A-Award | 140,000.00 | $1.80 | $252,000 |
| 2025-10-21 | Galzahr Karim | A-Award | 140,000.00 | $1.80 | $252,000 |
| 2025-10-21 | Ciccio John | A-Award | 140,000.00 | $1.80 | $252,000 |
| 2025-10-21 | Acevedo Christopher P. | A-Award | 200,000.00 | $1.80 | $360,000 |
| 2025-10-21 | McKean-Dieser Avril Suzette | A-Award | 140,000.00 | $1.80 | $252,000 |
| 2025-05-09 | Auerbach Shalom | 0.00 | $0.00 | $0 | |
| 2025-05-07 | Auerbach Shalom | S-Sale | 82,000.00 | $2.00 | $163,918 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for OSTX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for OSTX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.361 · dbb547f5 · 2026-07-01 10:01:38